Minerva Neurosciences, Inc. financial data

Symbol
NERV on Nasdaq
Location
1601 Trapelo Road, Suite 286, Waltham, MA
State of incorporation
DE
Fiscal year end
December 31
Latest financial report
10-Q - Q2 2024 - Aug 6, 2024

Key Ratios

Label TTM Value / Value Unit Change %
Current Ratio 1.15K % -47.4%
Debt-to-equity -267 % +36.1%
Return On Equity 104 % -28.9%
Return On Assets -62.1 % -35.3%

Shares

Label TTM Value / Value Unit Change %
Entity Common Stock, Shares Outstanding 6.99M shares 0%
Common Stock, Shares, Outstanding 6.99M shares 0%
Entity Public Float 36.9M USD +116%
Common Stock, Value, Issued 699 USD 0%
Weighted Average Number of Shares Outstanding, Basic 7.57M shares +37.3%
Weighted Average Number of Shares Outstanding, Diluted 7.57M shares +37.3%

Income Statement

Label TTM Value / Value Unit Change %
Research and Development Expense 16.2M USD +60.3%
General and Administrative Expense 10M USD -0.28%
Operating Income (Loss) -26.2M USD -30.1%
Net Income (Loss) Attributable to Parent -33.6M USD -25.6%
Earnings Per Share, Basic -4.4 USD/shares +11.6%
Earnings Per Share, Diluted -4.4 USD/shares +11.6%

Balance Sheet

Label TTM Value / Value Unit Change %
Cash and Cash Equivalents, at Carrying Value 30.9M USD -40.4%
Assets, Current 31.4M USD -39.9%
Property, Plant and Equipment, Net 8.16K USD -40%
Goodwill 14.9M USD 0%
Assets 46.3M USD -31.1%
Accounts Payable, Current 828K USD +178%
Liabilities, Current 4.2M USD +120%
Liabilities 90.8M USD +14%
Retained Earnings (Accumulated Deficit) -414M USD -8.86%
Stockholders' Equity Attributable to Parent -44.5M USD -256%
Liabilities and Equity 46.3M USD -31.1%

Popular Metrics

Label TTM Value / Value Unit Change %
Net Cash Provided by (Used in) Operating Activities -6.09M USD -5181%
Net Cash Provided by (Used in) Financing Activities 0 USD
Net Cash Provided by (Used in) Investing Activities 0 USD
Common Stock, Shares Authorized 125M shares 0%
Common Stock, Shares, Issued 6.99M shares 0%
Common Stock, Par or Stated Value Per Share 0 USD/shares 0%
Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect -6.09M USD -5181%
Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents 31M USD -40.3%
Deferred Tax Assets, Valuation Allowance 96.9M USD +7.5%
Deferred Tax Assets, Gross 96.9M USD +7.5%
Deferred Tax Assets, Operating Loss Carryforwards 34.5M USD +29.2%
Preferred Stock, Shares Issued 0 shares
Preferred Stock, Shares Authorized 100M shares 0%
Unrecognized Tax Benefits 0 USD
Preferred Stock, Shares Outstanding 0 shares
Deferred Tax Assets, Net of Valuation Allowance 431 USD -51.6%
Share-based Payment Arrangement, Expense 1.75M USD -41%
Preferred Stock, Par or Stated Value Per Share 0 USD/shares 0%